Clinical Trials
STRIDE Plus Lenvatinib and TACE Improves Progression-Free Survival in Hepatocellular Carcinoma
Kudo et alThe Lancet Oncology

The phase 3, global, randomised, open-label EMERALD-3 study evaluated durvalumab and tremelimumab (STRIDE) with or without lenvatinib combined with transarterial chemoembolisation (TACE) in patients with embolisation-eligible hepatocellular carcinoma (HCC). The combination of STRIDE, lenvatinib, and TACE achieved a statistically significant improvement in progression-free survival compared to TACE alone. These results support a STRIDE-based regimen as a potential new treatment strategy for this patient population, with additional clinical follow-up ongoing to evaluate final overall survival.
Key Takeaways
- STRIDE plus lenvatinib combined with transarterial chemoembolisation (TACE) demonstrated a statistically significant improvement in progression-free survival compared to TACE alone.
- Findings support a STRIDE-based combination regimen as a potential new therapeutic option for embolisation-eligible hepatocellular carcinoma, with final overall survival analysis awaiting ongoing follow-up.
Read the original sourceThe Lancet Oncology
